## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -6.9% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($367.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion**
- Source: Simply Wall Street | 20251223T030906 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) recently entered the NASDAQ-100 and announced a $250 million manufacturing expansion, following a strong share price performance and significant R&D progress. While the stock trades near record highs, various valuation models suggest it might still be undervalued. Investors are faced with the dilemma of whether this represents a fresh entry point or if future growth is already priced in.

**2. Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesdayâ€™s open (Dec. 23)**
- Source: ts2.tech | 20251223T030906 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) made its debut on the Nasdaq-100 on December 22, 2025, a significant mechanical event influencing near-term stock flows. The article details ALNY's Monday close and after-hours trading, alongside other recent company developments like a $250 million manufacturing expansion, board changes, and a partial repurchase of convertible notes. Investors are focused on the impact of the Nasdaq-100 inclusion, the company's strong commercial growth, pipeline ambitions, and analyst forecasts ahead of Tuesday's market open in a holiday-shortened week.

**3. Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook**
- Source: ts2.tech | 20251222T170938 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) has officially joined the Nasdaq-100 Index, a move expected to boost market visibility and institutional ownership. This inclusion follows a strong year driven by the commercial success of its drug AMVUTTRA, robust financial performance in Q3 2025, and a raised revenue outlook for the year. The article also highlights strategic investments in manufacturing expansion, global approvals, and advancements in drug delivery technology, alongside analyst price targets and potential risks.

**4. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages**
- Source: MarketBeat | 20251221T200906 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average "Moderate Buy" rating from 28 analysts, with a mean one-year price target of $477.44. While insiders have recently sold shares, institutional investors have significantly increased their stakes, holding nearly 93% of the company's shares. The company's stock shows a one-year low of $205.87 and a high of $495.55, with a current market capitalization of $52.87 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Leerink Partner | $351 | $370 | -5% |
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Leerink Partner | main | Market Perform |
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Near-term weakness: 10.2% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 35.7x attractive for 126% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 44% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $52.7B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 35.7 |
| Current P/E | 80.5 |
| YoY Growth | 125.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 10.9pp (needs >4.0% for momentum thesis). AM_20 at -6.0% indicates price below own 20MA trend. Underperforming sector by 6.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-1.68), momentum weakening. Elevated volume (3.0x 20MA), institutional activity likely. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.88% (CS: 6) | Weak |
| RSI_14 | 37.8 | Neutral |
| MACD Histogram | -1.68 | Bearish |
| vs SMA20 | 0.940x | Below |
| vs SMA50 | 0.898x | Below |
| vs SMA200 | 1.086x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $398.70
- **Stop Loss:** $367.90 (7.7% risk)
- **Target:** $429.50 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $15,150.60
- **Portfolio %:** 15.15%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*